297 related articles for article (PubMed ID: 33991077)
21. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
23. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
[TBL] [Abstract][Full Text] [Related]
25. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers.
Volkin D; Turkbey B; Hoang AN; Rais-Bahrami S; Yerram N; Walton-Diaz A; Nix JW; Wood BJ; Choyke PL; Pinto PA
BJU Int; 2014 Dec; 114(6b):E43-E49. PubMed ID: 24712649
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer.
Cerantola Y; Dragomir A; Tanguay S; Bladou F; Aprikian A; Kassouf W
Urol Oncol; 2016 Mar; 34(3):119.e1-9. PubMed ID: 26602178
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men.
Pahwa S; Schiltz NK; Ponsky LE; Lu Z; Griswold MA; Gulani V
Radiology; 2017 Oct; 285(1):157-166. PubMed ID: 28514203
[TBL] [Abstract][Full Text] [Related]
29. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia.
Gordon LG; James R; Tuffaha HW; Lowe A; Yaxley J
J Magn Reson Imaging; 2017 May; 45(5):1304-1315. PubMed ID: 27726240
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
Magnani CJ; Hernandez-Boussard T; Baker LC; Goldhaber-Fiebert JD; Brooks JD
J Urol; 2022 Jul; 208(1):80-89. PubMed ID: 35212570
[TBL] [Abstract][Full Text] [Related]
32. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
34. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
Kang SK; Mali RD; Prabhu V; Ferket BS; Loeb S
Radiology; 2021 Sep; 300(3):594-604. PubMed ID: 34254851
[TBL] [Abstract][Full Text] [Related]
35. Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer.
Thurtle D; Barrett T; Thankappan-Nair V; Koo B; Warren A; Kastner C; Saeb-Parsy K; Kimberley-Duffell J; Gnanapragasam VJ
BJU Int; 2018 Jul; 122(1):59-65. PubMed ID: 29438586
[TBL] [Abstract][Full Text] [Related]
36. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore.
Cheng LJ; Soon SS; Tan TW; Tan CH; Lim TSK; Tay KJ; Loke WT; Ang B; Chiong E; Ng K
BMC Health Serv Res; 2021 Sep; 21(1):909. PubMed ID: 34479565
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of Multiparametric MRI in 800 Men Submitted to Repeat Prostate Biopsy: Results of a Public Health Model.
Pepe P; Pepe G; Pepe L; Garufi A; Priolo GD; Pennisi M
Anticancer Res; 2018 Apr; 38(4):2395-2398. PubMed ID: 29599367
[TBL] [Abstract][Full Text] [Related]
39. Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial.
Wallström J; Geterud K; Kohestani K; Maier SE; Månsson M; Pihl CG; Socratous A; Arnsrud Godtman R; Hellström M; Hugosson J
Eur Radiol; 2021 Nov; 31(11):8692-8702. PubMed ID: 33890152
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
Keeney E; Sanghera S; Martin RM; Gulati R; Wiklund F; Walsh EI; Donovan JL; Hamdy F; Neal DE; Lane JA; Turner EL; Thom H; Clements MS
Pharmacoeconomics; 2022 Dec; 40(12):1207-1220. PubMed ID: 36201131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
